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Abstract: Tuberculosis (TB) and chronic obstructive pulmonary disease (COPD) carry a 
signiﬁ  cant burden in terms of morbidity and mortality worldwide. This review article focuses 
on different aspects of Tuberculosis in terms of the relationship with COPD such as in the 
development of chronic airﬂ  ow obstruction as a sequel to active TB and reviewing the key role 
of cigarette smoking in the pathogenesis of both conditions. Patients diagnosed with TB may 
often have extensive co-morbidity such as COPD and the effect of an underlying diagnosis of 
COPD on outcomes in TB is also reviewed.
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Introduction
Despite many advances in modern medicine, mankind’s old adversary tuberculosis 
(TB) remains a signiﬁ  cant public health problem both in developed countries as well 
as in developing world. Similarly, chronic obstructive pulmonary disease (COPD) 
carries a signiﬁ  cant burden worldwide in terms of morbidity and mortality (Celli 
et al 2004). COPD is deﬁ  ned as a disease state characterized by airﬂ  ow limitation 
that is not fully reversible. The airﬂ  ow limitation is usually both progressive and 
associated with an abnormal inﬂ  ammatory response of the lungs to noxious particles 
or gases (Pauwels et al 2001). This article focuses on the inter-relationship between 
TB and COPD, describing the development of chronic airﬂ  ow obstruction as a 
sequel to TB, examining the signiﬁ  cance of tobacco smoking in the pathogenesis 
of TB and COPD and reviewing the role of immunological mediators common to 
both conditions in addition to exploring the nature of active TB in an individual 
with co-existing COPD.
Comparing the burden of tuberculosis and COPD
The etiological agent in tuberculosis is the bacillus Mycobacterium tuberculosis which 
represents one of many in the family of mycobacteria. The mode of spread among 
humans is via aerosol droplet transmission hence the lungs are often the focus of tu-
berculous disease although TB may present with disease in any organ system. In the 
1998 survey of TB cases in England and Wales, 62% were noted to exhibit pulmonary 
involvement (Rose et al 2001). In that survey, 38% had sole extra-pulmonary involve-
ment and this ﬁ  gure appeared to be increasing when compared to previous surveys 
undertaken in the same region (Kumar et al 1997; Rose et al 2001). 
Up to 2 billion people, representing a third of the world’s population, have been 
infected with the tubercle bacillus ie, have latent TB infection (Dye et al 1999). In 
immunocompetent individuals with latent infection, 10% will develop active TB International Journal of COPD 2007:2(3) 264
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during their lifetime, a ﬁ  gure that climbs to 50% in the 
immuno-compromised (Dye et al 1999; Raviglione et al 
2003). Unsurprisingly, the re-emergence of TB as a major 
threat to global health has gone hand in hand with the world-
wide epidemic of human immunodeﬁ  ciency virus (HIV). 
There is increasing evidence that co-infection with TB ac-
celerates the progress of HIV in an individual and up to a 
third of AIDS related deaths worldwide have been attributed 
to TB (Cahn et al 2003). In addition, individuals with im-
paired cell mediated immunity often have false negative 
result with tuberculin skin testing and active TB with HIV 
co-infection progresses more rapidly as well as presenting 
with atypical clinical presentations and radiological appear-
ances. Poor compliance with anti-tuberculous medications 
not only results in inadequate treatment potentially causing 
considerable individual morbidity and mortality but may 
also lead to infection of close contacts as well as promot-
ing the spread of multi-drug resistant disease. Multi-drug 
resistant (MDR) TB, deﬁ  ned as resistance to at least 2 ﬁ  rst 
line anti-tuberculous drugs rifampicin and isoniazid, often 
a difﬁ  cult problem in immunocompetent patients, carries a 
signiﬁ  cantly increased mortality in the immunocompromised 
(Drobniewski et al 2002).These problems has been tackled 
in many different ways such adopting a Directly-Observed-
Treatment Strategy or DOTS (Uplekar et al 1999; Lienhardt 
et al 1999). However, the burden of TB is not limited just 
to developing countries. In many developed countries such 
as the United Kingdom (UK), TB has again undergone 
resurgence as a signiﬁ  cant public health problem driven 
by a number of factors including an increasing immigrant 
population from high TB prevalence areas, the impact of HIV 
and a previously complacent attitude amongst healthcare and 
governmental organisations towards the disease. 
Unfortunately, both COPD and tuberculosis share certain 
similarities in terms of carrying a considerable burden to the 
health of populations. Despite this, management strategies 
of both conditions have, in the past, suffered from a lack of 
political commitment and initiative. However, in 1993, the 
world health organisation (WHO) declared tuberculosis a 
“global emergency” (Kochi et al 1991).Worldwide, 8 mil-
lion new cases of active TB are reported (Dye et al 1999; 
Raviglione et al 2003).
The prevalence of COPD is, however, difficult to 
determine with precision due to under diagnosis as the symp-
toms may only become apparent only after a considerable 
loss of lung function (Pena et al 2000). This is coupled with 
the fact that spirometry (which is fundamental in order to 
diagnose COPD) may not be readily available in all regions. 
In a UK study, the overall prevalence of COPD diagnosed in 
primary care had progressively increased from 1990 to 1997, 
particularly in the female population (Soriano et al 2000). 
In a large study from Spain, the prevalence of COPD was 
estimated at 9.1%; only 21.8% of cases had been previously 
diagnosed (Pena et al 2000). The global prevalence of COPD 
in adults aged 40 years or over as deﬁ  ned by spirometry was 
estimated at 9%–10% (Halbert et al 2006). In terms of global 
mortality, TB is responsible for 2 million deaths annually 
(Dye et al 1999; Raviglione et al 2003). Worryingly, the death 
rate from COPD in the USA was shown to have increased by 
163% from 1965 to 1998 whilst deaths from coronary artery 
disease and stroke fell by 59% and 64% respectively (Pauwels 
et al 2001). COPD is currently the 5th leading cause of death 
worldwide and projected to rise to become the 3rd leading 
cause of death by 2020 (Pauwels et al 2001; Murray et al 
1997). This ranking is the result of the increasing prevalence 
of tobacco smoking and changes in population demographics 
resulting in an increased population of elderly (particularly 
female) smokers susceptible to loss of lung function with 
its clinical sequelae. Today, 1.1 billion people smoke and 
this appears set to increase to 1.6 billion by 2020 (Pauwels 
et al 2001) In essence, the world is facing a growing threat 
from tuberculosis as well as COPD due to various factors 
in relation to each condition such as the epidemic of HIV, 
increasing immigration, a rise in cigarette smoking and an 
attitude of complacency both by politicians and health care 
professionals.
In terms of health economics, 24 million working days 
are lost due to COPD in the UK (Calverley et al 1998). In 
the UK, the overall annual cost to the national health service 
(NHS) was estimated at £846 million in 1996 (National 
Health Service Executive 1996). A US study concluded that 
the total cost of COPD morbidity and morality amounted to 
$23.9 billion in 1993 (Sullivan et al 2000). In 1999, COPD 
was estimated to be the 12th leading cause of disability 
adjusted life years (DALYs) worldwide and it is predicted 
to rise to become the 5th leading cause by 2020 (Lopez et al 
1998; Michaud et al 2001). The economic impact of TB is no 
less important. Tuberculosis predominantly affects a young 
working population in developing countries at the prime 
of life compared to COPD which tends to affect an older 
population. This is highlighted in a paper from India evaluat-
ing 304 patients with TB where the total cost per individual 
was estimated at $171 per person representing a signiﬁ  cant 
ﬁ  nancial burden to the population of many developing nations 
(Rajeswari et al 1999). The mean age of the study popula-
tion was 37.8 years with 69% of males and 84% of females International Journal of COPD 2007:2(3) 265
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falling in the “economically productive” age group (15–49 
years).Tuberculosis ranked 7th in leading cause of death 
and disability worldwide in 1990 and is projected to remain 
7th by 2020 contributing to 42.5 × 106 DALYS (Lopez et al 
1997; Michaud et al 2001).
Susceptibility of an individual to the development of 
active tuberculosis and COPD involve a complex interaction 
between genetic and environmental factors which is currently 
poorly understood. A pattern of Mendelian susceptibility to 
TB has been described both in the paediatric as well as in the 
adult population (Casanova et al 2002; Alcais et al 2005). For 
example, in a Moroccan study of 96 families each containing 
2 siblings presenting with active pulmonary TB, susceptibility 
was linked to a region of chromosome 8q12–q13 (Baghdadi 
et al 2006). Genetic and host factors play an important 
role in the development of COPD illustrated by the fact 
that not all smokers go on to develop airﬂ  ow obstruction 
(Lundback et al 2003). Currently, the only known genetic 
abnormality pre-disposing to disease development is that of 
severe alpha-1-anti-trypsin deﬁ  ciency or PiZZ phenotype 
(Rennard et al 1998). However, even outside the context of 
alpha-1-anti-trypsin deﬁ  ciency, siblings of COPD patients 
have been shown to be more susceptible to develop abnormal 
lung function and familial clustering of COPD has been 
described (McCloskey et al 2001). Other candidate genes are 
currently being investigated such as those orchestrating the 
matrix metalloproteinase (MMP) system, tumour necrosis 
factor (TNF-α) and Interleukin-13 among others (Molﬁ  no 
et al 2004). However, a key limitation with some genetic 
studies lie in a failure to achieve reproducible data due to the 
relatively small number of patients studied in the presence of 
a heterogeneous study population eg, differences in ethnicity 
and lifestyle. Clearly, further research in this important area 
is needed.
In terms of treatment, it should not be forgotten that 
tuberculosis is a largely curable condition with anti-
tuberculous medications representing the cornerstone of 
management. At a simplistic level, cure may be achieved 
provided an individual has access to basic healthcare facilities 
capable of diagnosing the condition (often requiring only 
sputum analysis and chest radiography with an appropriate 
history) and is able to gain access to and comply with regular 
anti-tuberculous chemotherapy. Unfortunately, the greatest 
impact of Tuberculosis is felt in developing countries 
where conversely, many lack access to any such healthcare 
facilities and essential anti-tuberculous medications. On the 
other hand, COPD is characterized by its progressive nature; 
patients often presenting to a health care professional with 
symptoms only after a considerable degree of impairment 
to lung function has already been sustained. Reversal of the 
underlying insult is not possible at such a stage thus outlining 
the importance of identifying individuals with COPD at an 
early stage of the disease process by means of spirometry 
so that smoking cessation will achieve the greatest impact 
as well as promoting greater public awareness of COPD. In 
essence, the only interventions shown to inﬂ  uence mortality 
in COPD to date are smoking cessation, long term oxygen 
therapy (LTOT) and, lung volume reduction surgery (LVRS) 
in a selected subgroup of individuals (Pauwels et al 2001). 
Table 1 summarizes some key issues examining comparisons 
between COPD and Tuberculosis.
The role of cigarette smoking in the 
pathogenesis of TB and COPD
Tobacco smoking is a major aetiological factor in the 
development of COPD. The association between cigarette 
smoking, accelerated loss of lung function and COPD is well 
established (Fletcher et al 1977). Susceptible smokers have an 
accelerated decline in FEV1 over and above any age related 
changes seen in non-smokers. Eventually over years, this 
loss of lung function leads to progressive airﬂ  ow obstruction, 
development of disability and symptoms such cough, wheeze 
and breathlessness initially on exertion then ultimately at rest. 
Such a disease spiral is accompanied by deterioration in gas 
exchange and worsening respiratory failure, Cor Pulmonale 
and death. Smoking cessation has been shown to reduce this 
accelerated decline in FEV1 hence preventing or delaying the 
onset of signiﬁ  cant disability.
Controversy exists regarding the exact role of tobacco 
smoking in Tuberculosis. Several early studies supported an 
association between tobacco smoking and the tendency to 
develop TB. A large study from England in 1967 examined 
over 76,000 subjects undergoing chest radiography (Adel-
stein et al 1967). The rate of tuberculosis infection was re-
ported as being over 3 and 4 times higher for men and women 
respectively who were over 35 and smoking more than 20 
cigarettes daily. These ﬁ  ndings were consistent with previous 
studies published in the 1950s illustrating an increased risk 
of tuberculosis with the greater number of cigarettes smoked 
(Lowe et al 1956; Edwards et al 1957). However, a major 
methodological limitation to these early studies lay in the 
fact that socio-economic status was not taken into account. 
More recently, a questionnaire based study from America 
conducted between 1988–90 examined 151 TB patients and 
545 controls concluding that there was a 2.6 fold (95% CI 
1.1–5.9) increased risk of developing TB in those with a International Journal of COPD 2007:2(3) 266
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Table 1 Key comparisons between tuberculosis and COPD
 Tuberculosis  COPD
Epidemiology  Increasing incidence noted worldwide  Worldwide prevalence in adults 40
  contributed by epidemic of HIV among  years estimated at 9–10% (Halbert et al 
  other factors; in western world,  2006); prevalence increasing due to rise 
  incidence higher in immigrants  in cigarette smoking (particularly in
  originating from high prevalence areas  females) and an increasing elderly in
  (Dye et al 2006);   population hence resulting greater
    susceptibility to loss of lung function
  Predominantly affects young adults  Predominantly affects older adults
    (usually over 40 years)
Burden: Current and future ranking in  7th leading cause of DALYs in 1990  12th leading cause of DALYs in 1999;
disability adjusted life years (DALYs)  projected to remain 7th in 1990 (Murray et al  (Michaud et al 2001); estimated to the
  1997; Michaud et al 2001)  5th leading cause in 2020 (Lopez et al
   1998)
Burden: Current and future mortality  Currently 7th leading cause of death  Currently 5th leading cause of death 
  worldwide; will remain the 7th leading  worldwide; Projected to become the 3rd
  cause in 2020 (Murray et al 1997)  leading cause of death by 2020 (Murray
    et al 1997)
Disease susceptibility and inheritance  Evidence of genetic susceptibility with a  Interaction between host, genetic and
  Mendelian pattern of inheritance   environmental factors (McCloskey et al
  (Casanova et al 2002; Alcais et al 2005;  2001; Pauwels et al 2001)
  Baghdadi et al 2006)
  Complex interaction between genetic and   Environmental factors central to disease
  environmental factors; some evidence  development eg, cigarette smoke,
  that cigarette smoking may alter clinical  biomass fuels in developing countries
  presentation of TB (Shprykov et al  (Pauwels et al 2001)
  1994; Leung et al 2003) as well as   Genetic factors eg, alpha-1 anti-trypsin
  increasing risk of developing active  deﬁ  ciency interact with environmental
  disease (Maurya et al 2002; Davies et al 2006)  exposure; familial clustering reported
    (McCloskey et al 2001)
Pathogenesis  Involvement of matrix   Involvement of matrix
  metalloproteinase (MMP) system  metalloproteinase (MMP) system
  among others resulting in characteristic  resulting in parenchymal destruction
  parenchymal destruction (Hrabec et al  although many other factors involved at
  2002; Price et al 2003; Elkington et al  this and at the airway level (Braunhut 
  2005; Elkington et al 2006)  et al 1994; Finlay et al 1997;
  Sequelae of tuberculosis include   Frankenberger et al 2001; Imai et al
  development of chronic airﬂ  ow   2001; Mao et al 2003; Vernooy et al
  obstruction and bronchiectasis (Grancher   2004; Higashimoto et al 2005)
  1878; Jones et al 1950; Bromberg et al
  1963; Frame et al 1987; Nicotra et al
  1995; Hnizdo et al 2000; Park et al
  2001; Palwatwichai et al 2002; Lee et al
  2003; Ramos et al 2006; 67–76)
Treatment  Curable in the majority of cases with  Not curable; To date, only smoking
  appropriate anti-tuberculous  cessation and LTOT shown to inﬂ  uence
  chemotherapy; Potential for  mortality with LVRS in a selected 
  development of chronic airﬂ  ow  sequelaesubgroup (Pauwels et al 2001)
  obstruction and bronchiectasis among sequelae
20 year or greater smoking history (Buskin et al 1994). An 
interesting case-control study from Spain examined 46 cases 
of active TB comparing these to 46 “control” subjects who 
were deﬁ  ned as having a positive tuberculin skin test in the 
absence of any clinical or radiological features of active 
TB (Alcaide et al 1996). Smoking history was obtained by 
means of questionnaires and reinforced by patient interview 
and urinary cotinine levels were also measured with sub-
jects being divided into active smokers, passive smokers 
and non-smokers. The Odds Ratio (OR) for active cigarette International Journal of COPD 2007:2(3) 267
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smoking and the development of TB was 3.6 (1.5–2.2) and 
was deemed statistically signiﬁ  cant (p < 0.01). The authors 
clearly showed an increase in risk with a greater number of 
cigarettes smoked. The association between passive smoking 
did not however reach signiﬁ  cance in this study.
A 1996 study from Hong Kong examined 851 patients 
from the TB notiﬁ  cation registry (Leung et al 2003). The 
OR for ever smoking in both men and women diagnosed 
with active tuberculosis was greater than 2 when compared 
with healthy population controls. Socio-economic status was 
taken into account in this study with no signiﬁ  cant differences 
noted between smokers and non-smokers diagnosed with 
TB in terms of socio-economic status as well as ethnicity 
and body weight. In addition, several reviews of this subject 
taking these and other studies into account concluded that 
cigarette smoking increased the risk of developing active 
tuberculosis, perhaps between three and ﬁ  ve fold in a recent 
article (Maurya et al 2002; Davies et al 2006).
There is some data to suggest that tobacco smoking 
may also appear to alter the clinical presentation of TB. 
In the paper by Leung et al having ever smoked increased 
the likelihood of having cough and dyspnoea as presenting 
symptoms of TB (Leung et al 2003). Radiologically, TB 
patients who had ever smoked were more likely to exhibit 
cavitation, miliary disease and upper zone involvement. 
Although the likelihood of a positive sputum smear was also 
higher in this group, smoking did not appear to affect sus-
ceptibility to anti-tuberculous chemotherapy. The authors 
concluded that there was more aggressive lung involvement 
found among those who had ever smoked. Other authors 
also seem to reach a similar conclusion demonstrating that 
TB in smokers takes on a more severe disseminated course, 
more extensive lung involvement and less cavity closure 
(Shprykov et al 1994).
Common mediators in the 
pathogenesis of  TB and COPD
The development and subsequent disease progression seen 
both in TB and COPD result in characteristic destructive 
parenchymal lung changes. A common link to the patho-
genesis of both conditions may lie in the destruction of 
the pulmonary extra-cellular matrix (ECM) comprised of 
collagen and elastin which is key to the structural integrity 
of the lung (Elkington et al 2006). In particular, the role of 
matrix metalloproteinases (MMPs) deserves special mention. 
MMPs are a family of naturally occurring protease enzymes 
capable of degrading the ECM. In conditions where there 
is altered or unregulated activity of MMP enzymes, there 
exists the potential for re-modelling and subsequent damage 
to the lung architecture. The antigenic wall component of 
mycobacterium tuberculosis, lioparabinomannan (LAM), 
stimulates the release of MMP-9 as well as up regulating 
genetic expression of MMP-1 and MMP-9. This not only 
results in the breakdown of collagen in the ECM but is 
also stimulates further lung damage by activation of other 
immune mediators such as Interleukin-8 and other cytokines. 
This process may be central to the development of cavita-
tory parenchymal lung damage often complicating active 
tuberculosis that is familiar to the clinician. Hrabec et al 
demonstrated that MMP-9 levels were three times higher in 
the serum of tuberculosis patients compared with controls 
with increasingly elevated levels seen in those patients 
exhibiting advanced disease compared to limited disease 
(Hrabec et al 2002). Elkington et al found increased expres-
sion of MMP-1 and MMP-7 in the granulomas of patients 
with active TB compared with controls as well as increased 
MMP-1 secretion from the airway epithelial cells adjacent to 
these granulomas (Elkington et al 2005). Furthermore, this 
study also showed that activity of the speciﬁ  c inhibitor of 
MMP-1, tissue inhibitor of metalloproteinase 1 (TIMP-1), 
was suppressed resulting in unchecked MMP-1 activity and 
the potential for signiﬁ  cant destruction of the ECM. TNF-
alpha, which plays an important role in the formation of 
tuberculous granulomas, has been demonstrated to stimulate 
MMP-9 secretion from granulomas cultured from patients 
with active tuberculosis (Price et al 2003).
Many studies have demonstrated an association between 
MMPs and the development of structural lung damage com-
plicating tobacco related COPD. Finlay et al compared the 
expression of MMPs from alveolar macrophages taken from 
broncho-alveolar lavage (BAL) samples in 10 COPD patients 
and 10 control subjects (Finlay et al 1997). The group found 
signiﬁ  cantly more MMP transcription, in particular MMP-9, 
in the COPD group. Other studies have similarly found 
elevated levels of MMP-8 and MMP-9 in induced sputum 
and BAL samples taken from COPD patients (Vernooy et al 
2004). Imai et al compared lung parenchyma samples taken 
from 23 patients with COPD with 8 normal controls (Imai 
et al 2001). This study showed an increased level of MMP-1 
RNA activity in the COPD group which was not present in 
the control subjects. Furthermore, this group demonstrated 
that the source of such activity may originate from Type 2 
pneumocytes in the lung parenchyma. In contrast to that seen 
in TB patients, a recent study showed elevated serum TIMP-1 
levels in COPD patients compared to controls (Higashimoto 
et al 2005).International Journal of COPD 2007:2(3) 268
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The clear message from the literature is that increased 
expression of certain MMPs is associated with re-modelling 
of the pulmonary ECM and structural changes in the lung 
seen in both TB and COPD. Strictly, the above changes to 
the extra-cellular matrix would be expected to predominantly 
involve the lung parenchyma as opposed to the airways. 
Further studies are needed to correlate the degree of structural 
impairment related to the MMP system with physiological 
indices of pulmonary function focusing on airway physiol-
ogy, both in TB as well as COPD. Furthermore, the chal-
lenge remains whether pharmacologically targeting the 
matrix metalloproteinase network and other such mediators 
in these two conditions will result in clinically signiﬁ  cant 
outcomes. (Braunhut et al 1994; Frankenberger et al 2001; 
Mao et al 2003).
The impact of COPD 
as a co-morbidity in tuberculosis
There is little information in the literature about the impact 
of COPD co-morbidity in terms of prevalence, treatment 
outcomes and prognosis in TB. A study from Turkey 
which reviewed 5480 cases of active pulmonary and 
pleural TB found that COPD was the second most common 
co-morbid condition (Aktogu et al 1996). In that study, 6% 
of patients (331 cases) had a diagnosis of COPD which was 
second only to diabetes mellitus (8% of cases) and higher than 
narcotic abuse and alcoholism. Wang et al studied 461 cases 
of culture positive pulmonary TB in a tertiary referral centre 
in Taiwan (Wang et al 2005). In terms of concomitant non-
malignant diseases, a formal diagnosis of COPD was found 
in 31 cases again ranking second highest behind diabetes 
mellitus and ahead of renal failure, liver failure and HIV. 
In a study of tuberculous pleurisy cases by Liu et al COPD 
was again the 2nd most common co-morbid condition (found 
in 23% of cases) behind diabetes mellitus (Liu et al 2005). 
In that study, a diagnosis of COPD was not associated with 
case fatality. Furthermore, in a Romanian study, COPD was 
documented in 10.6% of cases of relapsed TB (Didilescu et 
al 2000). Perhaps not surprisingly, the prevalence of COPD 
as a co-morbid condition varies according to the age group 
studied. COPD has been found to be much more common in 
elderly patients diagnosed with TB. In a study from Pakistan, 
in terms of associated medical problems, COPD was found 
in 24.3% of elderly patients diagnosed with TB compared 
with only 3% of young cases (Rizvi et al 2003).
It is debatable whether the presence of COPD as a 
co-morbid condition represents a risk factor for mortality in 
cases of TB. In a UK study of 209 cases of culture positive pul-
monary TB, 19 patients died before completion of treatment. 
8 of these deaths were attributed to TB whilst 11 were from 
co-morbid conditions. Furthermore, 6 of these 11 deaths were 
as a result of COPD, all in white Caucasians with a male: fe-
male ratio of 4:2 (Ormerod et al 2002). In a 1990 study, COPD 
was listed as a concomitant disease in 5% of death certiﬁ  cates 
in patients dying from pulmonary TB (White et al 1996). In 
a cohort study of 139 patients treated for TB in the United 
States, 10% of patients had an underlying diagnosis of COPD 
(Oursler et al 2002). The authors concluded that the presence 
of COPD was an independent risk factor for death along with 
diabetes mellitus, renal disease and HIV infection. However, 
in a study from Baltimore, USA, a diagnosis of COPD was 
not associated with death from TB on multi-variate analysis 
(Fielder et al 2002). In this study of 174 patients diagnosed 
with TB, 23 cases had underlying COPD whilst 42 patients 
died whilst receiving anti-tuberculous chemotherapy.
A diagnosis of COPD may also be relevant in sicker TB 
patients eg, with drug resistance or those requiring intensive 
care unit (ICU) support. A Russian study of 309 civilians and 
291 prisoners found a prevalence of isoniazid resistance of 
60.2% and further suggested that this may be linked to an 
underlying diagnosis of COPD at an odds ratio of 2.1 (95% 
conﬁ  dence interval 1.0–4.3; p = 0.042) (Ruddy et al 2005). 
However, in a paper from Spain studying 276 cases of TB 
(24 drug resistant cases) over a 6 year period, COPD was 
not associated with the emergence of drug resistance on 
multi-variate analysis (Arevalo et al 1996). There were 33 
patients with COPD in the entire group but only 2 of these 
patients had drug resistant disease. Regarding TB patients 
requiring ICU support, a study of 58 patients with TB admit-
ted to a German ICU between 1990 and 2001 found that 6 of 
this group had an underlying diagnosis of COPD (Erbes et 
al 2006). 15 of the 58 patients died (4 of whom had COPD) 
compared with 43 who survived (2 of whom had COPD). 
Here, this difference in COPD prevalence was statistically 
signiﬁ  cant on uni-variate analysis (p = 0.03). However, there 
is comparatively little data on these sub-groups of TB patients 
in terms of associations with COPD and this area warrants 
further more detailed study.
The conﬂ  icting results from the above data examining the 
presence of underlying COPD as a risk factor for increased 
morbidity and mortality from TB may be due to the difﬁ  culty in 
adequately controlling for cigarette smoking. This is itself a risk 
factor for increased morbidity during the course of TB treatment 
as well as for the development of airﬂ  ow obstruction (Leung et al 
2003; Shprykov et al 1994). There is still less data in the literature 
on whether a diagnosis of COPD alters the clinical presentation International Journal of COPD 2007:2(3) 269
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of pulmonary TB. This is in contrast to data on other diseases 
affecting the outcome of TB such as diabetes mellitus despite 
COPD evidently being present in a substantial number of patients 
diagnosed with TB (Bacakoglu et al 2001).
The development of chronic 
airﬂ  ow obstruction as a sequel 
to pulmonary tuberculosis
Obstructive abnormalities in lung function may complicate 
pulmonary tuberculosis, particularly in long standing disease 
and if the extent of parenchymal involvement is extensive. 
Although, earlier studies regarding this issue were per-
formed in developed countries, the main burden is now felt 
in developing countries where there is both a high incidence 
of cigarette smoking and patients are more likely to present 
with extensive parenchymal lung destruction secondary to 
inadequately treated TB.
A major limitation in the interpretation of the early lit-
erature is due to the fact that such studies lacked an adequate 
control group making it difﬁ  cult to distinguish the effects 
of cigarette smoking from tuberculous infection in terms of 
effect on lung function measurements. In 1959, in a study 
of 1,533 patients, Gaensler et al showed that 61% had evi-
dence of airﬂ  ow obstruction (deﬁ  ned as an FEV1/FVC <70% 
and VC >80% predicted); 50% of patients had respiratory 
symptoms (64). Snider et al studied 1403 patients admitted 
to a Chicago Municipal TB Sanatorium over a 2 year pe-
riod between 1964 and 1966 (Snider et al 1971). 23% were 
noted to exhibit airﬂ  ow obstruction. Airﬂ  ow obstruction 
was more commonly noted among white Caucasian males 
more of whom also showed the most severe diminution 
of FEV1 to less than 50% predicted. The development of 
airﬂ  ow obstruction was linked to the presence of morning 
expectoration with 58.8% of males with expectoration hav-
ing obstructive spirometry compared with 42.4% without 
expectoration. There was no signiﬁ  cant association noted 
between smoking history in terms of pack years and the 
FEV1/FVC ratio. Abnormal spirometry was also not associ-
ated with the duration of active disease prior to presentation 
and only weakly with age. Meanwhile, a study from Sweden 
published in 1966 examined 488 patients with TB admitted to 
hospital over a 5 year period (Birath et al 1966). All patients 
underwent spirometry and chest radiography. A reduction of 
FEV1 as well as Vital Capacity (below 2 Standard deviations 
of predicted) was noted in 78 cases whilst a sole reduction 
in FEV1 was noted in 52 patients. The greatest frequency 
of respiratory symptoms (in terms of cough, expectoration, 
wheeze and allergic symptoms) was seen in those patients 
who had the greatest reduction in FEV1. Abnormalities in 
lung function were signiﬁ  cantly associated with increased 
duration of disease and age over 40. 12–15% of those deﬁ  ned 
as having “short” duration of disease (<1year) had abnormal 
lung function compared to 33–37% of those where disease 
duration was deﬁ  ned as “long” (>10 years). In addition, the 
prevalence of airﬂ  ow obstruction was signiﬁ  cantly greater 
in those patients labelled as having “generalized” tubercu-
lous disease (deﬁ  ned as lesions due to TB involving 75% or 
more of the chest radiograph). There were no gender related 
differences noted but the inﬂ  uence of cigarette smoking was 
not taken into account in this study.
A more recent paper from South Africa attempted to ex-
amine the impact of multiple episodes of treated TB on lung 
function (Hnizdo et al 2000). In this study, pulmonary function 
tests were performed on 27,660 black South African gold min-
ers. 2137 of the sample had previously suffered from at least 
1 episode, 366 from 2 episodes whilst 96 had 3 more episodes 
of active TB. 18.4% of those with 1 active TB episode devel-
oped chronic airﬂ  ow obstruction (deﬁ  ned here as FEV1<80% 
predicted) compared with 27.1% with 2 episodes and 35.2% 
in those with 3 or more. Following one episode of TB, the loss 
of FEV1 was highest 6 months post infection (326 mls) though 
the overall residual loss of FEV1 at the end of a minimal 12 
month follow up stabilized at 153mls. This compared to a fall 
in FVC by 305mls 6 months post infection which stabilized to 
a residual loss of 96 mls. However, again, there was no control 
group and the study population was not adjusted for smoking 
history nor were any speciﬁ  c effects of other dust exposure 
quantiﬁ  ed. Meanwhile, a smaller study from Brazil evaluated 
symptomatology and pulmonary function in 50 patients with 
pleuro-pulmonary sequelae of TB (Ramos et al 2006). In this 
study, those patients with an underlying diagnosis of COPD 
or asthma were excluded while 54% of the study population 
had never smoked. An obstructive ventilatory pattern alone 
was noted in 22% of patients with pulmonary TB whilst 34% 
exhibited a “mixed” obstructive and restrictive pattern. The 
authors found no signiﬁ  cant relationship between abnormali-
ties of pulmonary function and smoking history. However, 
the study did not take into account exposure to other noxious 
agents eg, biomass fuels often linked to the development of 
COPD in developing countries (Pauwels et al 2001). The 
severity of lung function impairment was proportional to the 
degree of radiographic involvement noted on the plain ﬁ  lm. 
Interestingly, the authors concluded that the presence of respi-
ratory symptoms did not predict altered pulmonary function.
A well described sequel to active tuberculosis is the 
development of bronchiectasis and subsequent airﬂ  ow ob-International Journal of COPD 2007:2(3) 270
Chakrabarti et al
struction (Grancher et al 1878).The exact incidence is dif-
ﬁ  cult to determine with precision. In the early 19th century, 
prior to the advent of more non invasive diagnostic tech-
niques, attempts to explore the incidence of bronchiectasis 
complicating TB relied on the analysis of autopsy material. 
In a study of 100 such autopsies, changes of bronchiectasis 
were described in 46% of cases (Jones et al 1950). Nowadays, 
bronchiectasis as a sequel to TB is seen less commonly in 
the developed world due to prompt diagnosis and improved 
access to anti-tuberculous chemotherapy. Nevertheless, 
bronchiectasis still complicates active pulmonary TB too 
frequently in developing countries. A prospective study 
from Thailand studied all patients (ﬁ  fty in total) diagnosed 
with bronchiectasis over a 2 year period from January 1998 
(Palwatwichai et al 2002). The mean age of the sample was 
58 years whilst 78% had never smoked. A history of TB 
was noted in 32% of the study population with the authors 
concluding that TB represented the most common aetiologi-
cal agent responsible for the development of bronchiectasis. 
Such data is in contrast to the ﬁ  ndings of a retrospective 
review of 363 adult bronchiectasis cases over an 8 year period 
in Texas, USA (Nicotra et al 1995). Here, only 9.8% of cases 
were attributed to “granulomatous” disease but this paper 
did not differentiate between tuberculosis and sarcoidosis 
as causative factors. In that study, bronchiectasis resulting 
from tuberculosis was described as more likely to occur in 
older individuals. However, such studies may be limited by 
the reliance of the patient describing a previous history of 
tuberculosis and the authors subsequently attributing this 
description as the deﬁ  nitive aetiology leading to the develop-
ment of subsequent bronchiectasis. 
Pathophysiology behind the 
development of chronic airﬂ  ow 
obstruction secondary to active 
tuberculosis
Very little exists in the literature comparing clinical and 
physiological characteristics of chronic airﬂ  ow obstruction 
(CAO) secondary to TB to that seen in patients with tobacco 
related COPD. A South Korean study followed 21 patients 
with chronic airﬂ  ow obstruction (CAO) secondary to TB 
as well as studying clinical characteristics and various lung 
function measurements (Lee et al 2003). All patients had 
parenchymal damage to more than half a lung as a result of 
proven TB yet had no evidence of active TB, currently did 
not smoke and had less than 20 pack year smoking history 
(mean 3.6 pack years). These data were compared with a 
control group of 11 patients diagnosed with tobacco related 
COPD whom by deﬁ  nition had >20 pack years smoking his-
tory (mean 44.1 pack years) with no radiographic evidence of 
pulmonary inﬁ  ltration. There were no signiﬁ  cant differences 
noted between the 2 groups in occurrence and frequency of 
symptoms of dyspnoea and cough though there was a trend 
towards a greater frequency of haemoptysis in the CAO 
patients. In addition, no signiﬁ  cant differences were observed 
between the 2 groups regarding exacerbation episodes and 
hospitalizations. Bronchodilator response was also studied 
in the 2 groups. A positive response (deﬁ  ned as an increase 
in FEV1 of 200 mls or 12%) was seen more frequently in the 
tobacco related COPD group compared to the CAO patients 
(82% vs 27%; p < 0.05). The FEV1 seen in the CAO group 
following bronchodilator inhalation was also signiﬁ  cantly 
lower than the COPD patients (1.15 l vs 1.37 l; p < 0.05). 
Airway resistance (Raw) was higher in the CAO group but 
this did not reach statistical signiﬁ  cance. 
The extent of airflow obstruction and parenchymal 
destruction seen as a result of TB infection may be so severe 
as to lead to the development of respiratory failure which 
may sometimes require acute ventilatory support (Park et al 
2001). Several studies have highlighted the mortality associ-
ated with the development of ventilatory failure in this group 
of patients (Erbes et al 2006; Park et al 2001; Frame et al 
1987). A study from South Korea retrospectively reviewed 
38 such patients admitted to the ICU requiring mechanical 
ventilation (Park et al 2001). Patients were predominantly 
male (65.8%) and 52% of the group had never smoked. 
Pulmonary function measurements had been performed in 
21 of these patients in the preceding 12 months. The mean 
FEV1 of this group was 0.77 litres (29.3% predicted), mean 
FVC of 1.52 litres (41% predicted) with a mean FEV1/FVC 
ratio of 55.1% suggesting that chronic airﬂ  ow obstruction 
secondary to TB plays a major role in the development of 
acute respiratory failure. However, the methodology of 
such studies were again limited due to a lack of adequate 
control subjects as well as retrospective data hence making 
it difﬁ  cult to separate the effects of tobacco smoking from 
tuberculosis infection as the primary cause of respiratory 
insufﬁ  ciency. It must not be forgotten that, particularly in 
developing countries, a diagnosis of tobacco related COPD 
may be a major contributory factor in the development of 
acute ventilatory failure complicating tuberculous infection 
(Erbes et al 2006; Park et al 2001).
The pathophysiology leading to the development 
of airﬂ  ow obstruction in TB is multi-factorial in nature 
(Bromberg et al 1963). Endobronchial involvement may International Journal of COPD 2007:2(3) 271
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result in localised and generalised bronchial obstruction, 
ﬁ  brosis and an increased airways resistance. There may be 
extrinsic bronchial compression secondary to tuberculous 
lymphadenopathy. Parenchymal lung destruction may also 
affect pulmonary compliance resulting in an increased 
tendency for peripheral airways collapse and subsequent 
air trapping. This is worsened by abnormalities in the 
ventilation-perfusion relationships. Parenchymal and airway 
changes result in areas of decreased ventilation which may 
be adequately perfused. Conversely, mycobacteria infection 
may induce vascular changes in the lung leading to a scenario 
of decreased perfusion in areas of adequate ventilation. 
Unsurprisingly therefore, the net result of the above is an 
impairment of lung function and the development of airﬂ  ow 
obstruction with abnormal gas exchange.
Summary
Worldwide, tuberculosis and COPD are common conditions 
carrying an immense burden on the health of populations and 
healthcare resources. The development of chronic airﬂ  ow ob-
struction and respiratory symptoms may be preceded by one or 
several episodes of active TB and is more likely following ex-
tensive and severe infection, particularly if this involves large 
areas if lung parenchyma radiologically. Tobacco smoking is 
central to the development of COPD in most cases and some 
evidence exists to support the role of smoking in inﬂ  uencing 
the progression and clinical course of TB infection. Immuno-
logical mediators affecting the lung parenchyma have been 
identiﬁ  ed that are common to the pathogenesis of COPD and 
TB. COPD also appears to be a common co-morbid condition 
in patients diagnosed with active TB though further studies 
are needed to determine whether the clinical presentation, 
disease progression and mortality from TB are affected by 
an underlying diagnosis of COPD.
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